Skip to main content

Table 2 Participants’ willingness to receive a transmission-blocking malaria vaccine depending on varying vaccine characteristics

From: Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study

 

Cahuide (n = 48)

12 de Abril (n = 17)

La Habana (n = 13)

San José de Lupuna (n = 27)

Santa Rita (n = 21)

San Pedro (n = 15)

Total (or Average) (n = 141)

Cost

 Only if free

22 (45.8%)

3 (17.6%)

4 (30.8%)

11 (40.7%)

8 (38.1%)

7 (46.7%)

55 (39.0%)

 Willing to pay

26 (54.2%)

14 (82.4%)

9 (69.2%)

16 (59.3%)

13 (61.9%)

8 (53.3%)

86 (61.0%)

 Average price (S./)a

8.7

9.4

10.0

2.6

4.3

2.8

6.6

 Modified price (S./)a

4.7

7.7

6.9

1.5

2.7

1.5

4.0

 Price range (S./)a

2—30

2—30

5—20

1—5

1—5

1—5

1—5

 

Cahuide (n = 48)

12 de Abril (n = 17)

La Habana (n = 13)

San José de Lupuna (n = 27)

Santa Rita (n = 22)

San Pedro (n = 15)

Total (n = 142)

Acceptable modes of administration for adults

 Injection

47 (97.9%)

17 (100%)

13 (100%)

27 (100%)

21 (95.5%)

13 (86.7%)

138 (97.2%)

 Drops in the mouth

46 (95.8%)

17 (100%)

13 (100%)

25 (92.6%)

21 (95.5%)

14 (93.3%)

136 (95.8%)

 Pill

44 (91.7%)

16 (94.1%)

12 (92.3%)

26 (96.3%)

21 (95.5%)

15 (100%)

134 (94.4%)

 

Cahuide (n = 39)

12 de Abril (n = 17)

La Habana (n = 11)

San José de Lupuna (n = 25)

Santa Rita (n = 19)

San Pedro (n = 13)

Total (n = 124)

Acceptable modes of administration for children

 Injection

34 (87.2%)

16 (94.1%)

10 (90.9%)

23 (92.0%)

18 (94.7%)

12 (92.3%)

113 (91.1%)

 Drops in the mouth

37 (94.9%)

17 (100%)

11 (100%)

24 (96.0%)

19 (100%)

12 (92.3%)

120 (96.8%)

 Pill

35 (89.7%)

17 (100%)

10 (90.9%)

22 (88.0%)

17 (89.5%)

13 (100%)

114 (91.9%)

 

Cahuide (n = 48)

12 de Abril (n = 17)

La Habana (n = 13)

San José de Lupuna (n = 27)

Santa Rita (n = 22)

San Pedro (n = 15)

Total (n = 142)

Number of injections acceptable for adults

 One

47 (97.9%)

16 (94.1%)

13 (100%)

27 (100%)

22 (100%)

13 (86.7%)

138 (97.2%)

 More than one

38 (79.2%)

14 (82.4%)

13 (100%)

25 (92.6%)

17 (77.3%)

11 (73.3%)

118 (83.1%)

 

Cahuide (n = 39)

12 de Abril (n = 17)

La Habana (n = 11)

San José de Lupuna (n = 25)

Santa Rita (n = 19)

San Pedro (n = 13)

Total (n = 124)

Number of injections acceptable for children

 One

35 (89.7%)

17 (100%)

10 (90.9%)

24 (96.0%)

18 (94.7%)

13 (100%)

117 (94.4%)

 More than one

28 (71.8%)

15 (88.2%)

10 (90.9%)

22 (88.0%)

13 (68.4%)

11 (84.6%)

99 (79.8%)

 

Cahuide (n = 48)

12 de Abril (n = 17)

La Habana (n = 13)

San José de Lupuna (n = 27)

Santa Rita (n = 22)

San Pedro (n = 15)

Total (n = 142)

Acceptable efficacy for adults (%)

100

48 (100%)

17 (100%)

13 (100%)

27 (100%)

22 (100%)

15 (100%)

142 (100%)

70

43 (89.6%)

15 (88.2%)

12 (92.3%)

25 (92.6%)

21 (95.5%)

12 (80.0%)

128 (90.1%)

50

29 (60.4%)

12 (70.6%)

10 (76.9%)

22 (81.5%)

17 (77.3%)

12 (80.0%)

102 (71.8%)

 

Cahuide (n = 39)

12 de Abril (n = 17)

La Habana (n = 11)

San José de Lupuna (n = 25)

Santa Rita (n = 19)

San Pedro (n = 13)

Total (n = 124)

Acceptable efficacy for children (%)

 100

39 (100%)

17 (100%)

11 (100%)

25 (100%)

19 (100%)

13 (100%)

124 (100%)

 70

35 (89.7%)

15 (88.2%)

10 (90.9%)

23 (92.0%)

17 (89.5%)

10 (76.9%)

110 (88.7%)

 50

22 (56.4%)

12 (70.6%)

8 (72.7%)

21 (84.0%)

15 (78.9%)

10 (76.9%)

88 (71.0%)

  1. aPrices are listed in Peruvian soles. In July–August 2014, S./1 ≈ $0.36 USD. Average price is the mean of the prices cited by those who were willing to pay for the vaccine. Modified price is the mean of all prices, including the price of S./0 cited by those who were only willing to receive the vaccine if it were free. Six participants were childless and 12 responded that they did not wish to respond on behalf of their adult children who could make their own vaccination decisions, accounting for n = 142 for adult responses and n = 124 for responses related to children